These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23332713)

  • 1. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments.
    Rex JH; Eisenstein BI; Alder J; Goldberger M; Meyer R; Dane A; Friedland I; Knirsch C; Sanhai WR; Tomayko J; Lancaster C; Jackson J
    Lancet Infect Dis; 2013 Mar; 13(3):269-75. PubMed ID: 23332713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical considerations associated with a comprehensive regulatory framework to address the unmet need for new antibacterial therapies.
    Dane A; Wetherington JD
    Pharm Stat; 2014; 13(4):222-8. PubMed ID: 24931419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B; Bartlett J; Wunderink R; Gilbert DN
    Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant Infections.
    Hwang TJ; Kesselheim AS
    Am J Law Med; 2016 May; 42(2-3):429-450. PubMed ID: 29086648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late stage antibacterial drugs in the clinical pipeline.
    Projan SJ; Bradford PA
    Curr Opin Microbiol; 2007 Oct; 10(5):441-6. PubMed ID: 17950658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
    Shimazawa R; Ikeda M
    Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans.
    Piana C; Kliphuis E; Della Pasqua O
    Clin Trials; 2013 Apr; 10(2):269-79. PubMed ID: 23335676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moving goalposts--regulatory oversight of antibacterial drugs.
    Brenner R; Ellis-Grosse EJ; Echols R
    Nat Biotechnol; 2006 Dec; 24(12):1515-20. PubMed ID: 17160053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH; Mohr JF
    Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic bill doesn't GAIN enough ground.
    Ambrose PG
    Nat Med; 2011 Jul; 17(7):772. PubMed ID: 21738147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
    Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
    Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good.
    Corey GR; Stryjewski ME
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S469-76. PubMed ID: 21546623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A long and winding road; evolution of antimicrobial drug development - crisis management.
    Echols RM
    Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1311-9. PubMed ID: 23241188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug development process for a product with a primary pediatric indication.
    Allen AJ; Michelson D
    J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International Conference on Harmonisation; guidance on ethnic factors in the acceptability of foreign clinical data; availability--FDA. Notice.
    Fed Regist; 1998 Jun; 63(111):31790-6. PubMed ID: 10180134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in developing new antibacterial drugs.
    Williams KJ; Bax RP
    Curr Opin Investig Drugs; 2009 Feb; 10(2):157-63. PubMed ID: 19197793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.